Trial Profile
A phase I/II open-label, dose-escalation study to determine the maximum tolerated dose and to evaluate the safety profile of lenalidomide (Revlimid) with liposomal doxorubicin in subjects with advanced ovarian and primary peritoneal carcinoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Doxorubicin liposomal
- Indications Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 29 Oct 2005 New trial record.